Table 5.
Associations between APS-related clinical manifestations of 212 patients with aPL levels.
| IgA | IgG | IgM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IgA–aPL positive (n = 34) | IgA–aPL negative (n = 178) | P | OR (95% CI) | IgG–aPL positive (n = 107) | IgG–aPL negative (n = 105) | P | OR (95% CI) | IgM–aPL positive (n = 57) | IgM–aPL negative (n = 155) | P | OR (95% CI) | |
| PAPS | 19 (55.88%) | 134 (75.28%) | 0.067 | 0.44 (0.183–1.061) | 64 (59.81%) | 89 (84.76%) | 0.001 | 0.259 (0.118–0.565) | 33 (57.89%) | 120 (77.42%) | 0.056 | 0.473 (0.219–1.020) |
| SAPS | 15 (44.12%) | 44 (24.72%) | 43 (40.19%) | 16 (15.24%) | 24 (42.12%) | 35 (22.58%) | ||||||
| Arterial thrombosis | 17 (50.00%) | 60 (33.71%) | 0.464 | 1.67 (0.423–6.599) | 45 (42.06%) | 32 (30.48%) | 0.540 | 1.388 (0.486–3.964) | 22 (38.60%) | 55 (35.48%) | 0.405 | 1.594 (0.532–4.778) |
| Venous thrombosis | 17 (50.00%) | 87 (48.88%) | 0.229 | 1.948 (0.657–5.773) | 58 (54.21%) | 46 (43.81%) | 0.175 | 1.861 (0.758–4.568) | 35 (61.40%) | 69 (44.52%) | 0.019 | 3.078 (1.200–7.896) |
| Pregnancy morbidity | 15 (44.12%) | 70 (39.32%) | 0.056 | 2.779 (0.973–7.942) | 36 (33.64%) | 49 (46.67%) | 0.896 | 1.061 (0.437–2.580) | 20 (35.09%) | 65 (41.94%) | 0.401 | 1.485 (0.590–3.733) |
| Stroke | 11 (32.35%) | 27 (15.17%) | 0.600 | 1.468 (0.350–6.163) | 25 (23.36%) | 13 (12.38%) | 0.692 | 1.3 (0.356–4.753) | 9 (15.79%) | 29 (18.71%) | 0.597 | 1.456 (0.361–5.881) |
| Cardiopulmonary involved | 10 (29.41%) | 42 (23.60%) | 0.478 | 0.674 (0.227–2.005) | 32 (29.91%) | 20 (19.00%) | 0.015 | 30.512 (1.969–472.780) | 13 (22.81%) | 39 (25.16%) | 0.401 | 0.351 (0.031–4.034) |
| Acute coronary syndrome | 1 (2.94%) | 6 (3.37%) | 0.887 | 0.826 (0.059–11.526) | 2 (1.87%) | 5 (4.76%) | 0.025 | 0.025 (0.001–0.641) | 1 (1.75%) | 6 (3.87%) | 0.852 | 1.279 (0.097–16.909) |
| Pulmonary embolism | 8 (23.53%) | 34 (19.1%) | 0.561 | 1.562 (0.347–7.042) | 25 (23.36%) | 17 (16.19%) | 0.042 | 0.058 (0.004–0.906) | 12 (21.05%) | 30 (19.35%) | 0.909 | 1.148 (0.107–12.315) |
| Valvular lesions | 3 (8.82%) | 6 (3.37%) | 0.365 | 2.374 (0.366–15.382) | 6 (5.61%) | 3 (2.86%) | 0.113 | 0.186 (0.023–1.487) | 1 (1.75%) | 8 (5.16%) | 0.394 | 0.32 (0.023–4.388) |
| Renal involved | 6 (17.65%) | 20 (11.24%) | 0.900 | 1.075 (0.348–3.318) | 18 (16.82%) | 8 (7.62%) | 0.319 | 1.673 (0.608–4.607) | 9 (15.79%) | 17 (10.97%) | 0.797 | 1.15 (0.395–3.345) |
| Autoimmune hemolytic anemia | 4 (11.77%) | 15 (8.43%) | 0.498 | 0.62 (0.156–2.472) | 11 (10.28%) | 8 (7.62%) | 0.160 | 0.431 (0.133–1.395) | 12 (21.05%) | 7 (4.52%) | 0.008 | 4.977 (1.512–16.387) |
| Thrombocytopenia | 22 (64.71%) | 78 (43.82%) | 0.146 | 1.922 (0.797–4.633) | 63 (58.88%) | 37 (35.24%) | 0.042 | 1.992 (1.024–3.872) | 30 (52.63%) | 70 (45.16%) | 0.484 | 0.769 (0.367–1.607) |